XpresSpa Group Signs Contract with Port of Seattle for an XpresCheck™ COVID-19 Pop-Up Testing Facility at Seattle-Tacoma International Airport
XpresSpa Group has announced the launch of its first XpresCheck COVID-19 testing facility on the West Coast, located at Seattle-Tacoma International Airport. Expected to begin operations by mid-March, the facility will feature eight testing rooms with a capacity for over 500 tests daily, offering both Rapid Molecular and PCR tests. This expansion strengthens XpresSpa's commitment to providing accessible testing services, particularly for travelers to Hawaii, and aligns with its long-term goals in the travel health and wellness sector.
- First XpresCheck testing facility on the West Coast.
- Expected to administer over 500 tests per day, enhancing testing capacity.
- Supports travel to Hawaii, a significant destination for travelers from Seattle.
- None.
First XpresCheck Testing Facility on the West Coast Expected to Commence Operations by mid-March
SEATTLE, March 04, 2021 (GLOBE NEWSWIRE) -- XpresSpa Group, Inc. (Nasdaq: XSPA) (“XpresSpa” or the “Company”), a health and wellness company, today announced that it has signed a contact with the Port of Seattle for an XpresCheck™ COVID-19 pop-up testing facility at Seattle-Tacoma International Airport (SEA). This is the Company’s first testing facility on the West Coast and it is expected to be fully-operational by mid-March.
XpresCheck will be building a pop-up facility pre-security in Baggage Claim near Carousel 9. It will host eight separate testing rooms with an anticipated capacity to administer over 500 tests per day. COVID-19 testing options will include the Rapid Molecular COVID-19 Test and the Polymerase Chain Reaction (PCR) Test.
Doug Satzman, XpresSpa CEO, stated, “We are excited to be launching XpresCheck at SEA Airport as it marks our first COVID-19 testing facility on the West Coast. Additionally, we are proud to be a trusted partner of Hawaiian Airlines and the state of Hawaii as several direct flights to Hawaii originate at SEA. This helps to make pre-travel testing accessible and seamless for passengers taking a long-awaited Hawaii vacation.”
Satzman continued, “Expanding the XpresCheck brand enables us to provide convenient, reliable COVID-19 testing and related medical services across a greater number of airports and further supports our long-term goal of becoming the leading brand in the Travel Health and Wellness category.”
About XpresSpa Group, Inc.
XpresSpa Group, Inc. (Nasdaq: XSPA) is a leading global health and wellness holding company. XpresSpa Group’s core asset, XpresSpa, is a leading airport retailer of spa services and related health and wellness products, with 45 locations in 23 airports globally. Through its XpresTest, Inc. subsidiary, the Company provides COVID-19 screening and testing under the XpresCheck™ brand at seven locations in six airports: Denver International Airport, JFK International Airport, Logan International Airport (2), Newark Liberty International Airport, Phoenix Sky Harbor International Airport, and Salt Lake City International Airport. To learn more about XpresSpa Group, visit: www.XpresSpaGroup.com.
Twitter: @xprescheck and Instagram: @realxprescheck
Forward-Looking Statements
Forward-Looking Statements This press release may contain "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These include statements preceded by, followed by or that otherwise include the words "believes," "expects," "anticipates," "estimates," "projects," "intends," "should," "seeks," "future," "continue," or the negative of such terms, or other comparable terminology. In particular, these statements include, without limitation, statements about our expectations relating to our new XpresCheck™ concept, being able to expand testing to other communicable diseases as well as administer vaccinations for the seasonal flu, our positioning to be part of the national rollout of various COVID-19 vaccinations as they become available, the degree to which our public testing model assists passengers meet testing requirements in select states and countries, our ability to identify and gain access to the latest and best COVID-19 testing methodologies and equipment, and our ability further expand our initial sites and our overall ability to manage the regulatory challenges associated with this business line. Forward-looking statements relating to expectations about future results or events are based upon information available to XpresSpa Group as of today's date and are not guarantees of the future performance of the company, and actual results may vary materially from the results and expectations discussed. Additional information concerning these and other risks is contained in XpresSpa Group’s most recently filed Annual Report on Form 10-K, Quarterly Report on Form 10-Q, recent Current Reports on Form 8-K and other Securities and Exchange Commission filings. All subsequent written and oral forward-looking statements concerning XpresSpa Group, or other matters and attributable to XpresSpa Group or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. XpresSpa Group does not undertake any obligation to publicly update any of these forward-looking statements to reflect events or circumstances that may arise after the date hereof.
Investor Relations:
ICR
Raphael Gross
ir@xpresspagroup.com
(203) 682-8253
Media:
Julie Ferguson
Julie@jfprmedia.com
(312) 385-0098
FAQ
What is the location of the first XpresCheck facility?
When will the XpresCheck facility at Seattle-Tacoma begin operations?
What types of COVID-19 tests will be offered at the XpresCheck facility?
How many tests can the XpresCheck facility administer daily?
What is XpresSpa's goal with these testing facilities?
